Dexmedetomidine: A Review of a Newer Sedative in Dentistry

Dexmedetomidine is a central α-2 agonist, similar to Clonidine, but 8 times more specific for the central α-2 receptor which causes sedation with minimal depression of respiration, making it safe for sedation during procedures. It is widely used in the field of medicine for many procedures especially premedication, awake intubation, and sedation of patients in intensive care units and pediatric procedural sedation. Objective: To do a systematic review of the pharmacology, pharmacodynamics, as well as the usage of newer sedative drug- Dexmedetomidine in dentistry. Study design: The search for articles was conducted in Pub Med, including the articles published in English until Oct 2014. Both animal and human studies were included using the key words, “Dexmedetomidine”, “Dexmedetomidine in sedation”, “Dexmedetomidine in Dentistry”, and “Dexmedetomidine in Pediatric dentistry”. The Articles obtained were checked for their quality methodology and inference of the studies and selected for review. Results: Initial search retrieved 2436 articles, out of which 44 articles were on the subject of Dexmedetomidine in dentistry. Five of which articles were on the usage of Dexmedetomidine in pediatric dentistry. These studies were included in systematic review. Conclusion: The study revealed that Dexmedetomidine being a new drug with its added advantages makes a better choice for sedation in dentistry. But with limited studies on Dexmedetomidine, the recommendation to use the drug exclusively is still under debate.

Analgesia, Dexmedetomidine, Intravenous, Sedation, Premedication, Review

1. Malamed SF. Pain and anxiety in dentistry. Sedation: A clinical guide to patient management, St. Louis, Mosby Elsevier; 2-7, 2010.

2. American Academy of Pediatric dentistry: Guideline for Monitoring and Management of Pediatric Patients During and After Sedation for Diagnostic and Therapeutic Procedures. Pediatr Dent; 36:209-25, 2011.

3. Hosey MT. Managing anxious children: The use of conscious sedation in paediatric dentistry. Int J Paediatr Dent; 12:359–72, 2002.

4. Carollo DS, Nossaman BD, Ramadhyani U. Dexmedetomidine: A review of clinical applications. Curr Opin Anaesthesiol; 21:457–61, 2008.

5. Cormack JR, Orme RM, Costello TG. The role of alpha2-agonists in neurosurgery. Journal of Clinical Neuroscience; 12: 375–8, 2005.

6. TVSP Murthy, Singh R. Alpha 2 adrenoceptor agonist - Dexmedetomidine role in anaesthesia and intensive care: A clinical review. Journal of Anaesthesiology Clinical Pharmacology; 25:267-72, 2009.

7. Venn RM, Bradshaw CJ, Spencer R. Preliminary UK experience of Dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia; 54:1136-42, 1999.

8. Hayashi Y, Maze M. α2-adrenoceptor agonists and anaesthesia. Br J Anaesth; 71: 108-18, 1993.

9. Piascik MT, Soltis EE, Piascik MM, Macmillan LB. α-adrenoceptors and vascular regulation: molecular, pharmacologic and clinical correlates. Pharmacol Ther, 72: 215-41, 1996.

10. Khan ZP, Ferguson CN, Jones RM. α2- and imidazoline-receptor agonists: Their pharmacology and therapeutic role. Anaesthesia; 54: 146-65, 1999.

11. Brummett CM, Padda AK, Amodeo FS, Welch KB, Lydic R. Perineural dexmedetomidine added to ropivacaine causes a dose-dependent increase in the duration of thermal antinociception in sciatic nerve block in rat. Anaesthesiology; 11:1111-9, 2009.

12. Lönnqvist PA. Alpha-2 adrenoceptor agonists as adjuncts to Peripheral Nerve Blocks in Children - is there a mechanism of action and should we use them? Paediatr Anaesth; 22:421-4, 2012.

13. Grewal A. Dexmedetomidine: New avenues. J Anaesthesiol Clin Pharmacol; 27:297-302, 2011.

14. Eisenach JC, De Kock M, Klimscha W. alpha (2)-adrenergic agonists for regional anesthesia. A clinical review of Clonidine (1984-1995) Anaesthesiology. 85:655–74, 1996.

15. Brummett CM, Norat MA, Palmisano JM, Lydic R. Perineural administration of dexmedetomidine in combination with bupivacaine enhances sensory and motor blockade in sciatic nerve block without inducing neurotoxicity in rat. Anaesthesiology; 109:502-11, 2008.

16. Schmeling WT, Kampine JP, Roerig DL, Warltier DC. The effects of the stereoisomers of the α2-adrenergic agonist medetomidine on systemic and coronary hemodynamics in conscious dogs. Anaesthesiology; 75: 499-511, 1991.

17. Kamibayashi T, Maze M. Clinical uses of α2-adrenergic agonists. Anaesthesiology; 93: 1345-9, 2000.

18. Hayashi Y, Maze M. α2-adrenoceptor agonists and anaesthesia. Br J Anaesth; 71: 108-18, 1993.

19. Maze M, Fujinaga M. α2-adrenoceptors in pain modulation: Which subtype should be targeted to produce analgesia? Anaesthesiology; 92: 934-6, 2000.

20. Abbott Laboratories. Precedex. Dexmedetomidine hydrochloride injection prescribing information. Abbott Laboratories, USA, 2000.

21. Bloor BC, Ward DS, Belleville JP, Maze M. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes. Anaesthesiology; 77:1134–42, 1992.

22. Buhrer M, Mappes A, Lauber R, Stanski DR, Maitre PO. Dexmedetomidine decreases thiopental dose requirement and alters distribution pharmacokinetics. Anaesthesiology; 80: 1216- 27, 1994.

23. Virkkila M, Ali-Melkkila T, Kanto J, Turunen J, Scheinin H. Dexmedetomidine as intramuscular premedication for daycare cataract surgery. A comparative study of dexmedetomidine, midazolam and placebo. Anaesthesia; 49: 853-8, 1994.

24. Maze M, Virtanen R, Daunt D, Banks SJ, Stover EP, Feldman D. Effects of dexmedetomidine, a novel imidazole sedative-anesthetic agent, on adrenal steroidogenesis: in vivo and in vitro studies. Anesth Analg; 73:204–8, 1991.

25. Laudenbach V, Mantz J, Lagercrantz H, Desmonts JM, Evrard P, Gressens P. Effects of α2-adrenoceptor agonists on perinatal excitotoxic brain injury: comparison of Clonidine and dexmedetomidine. Anaesthesiology; 96:134-41, 2002.

26. Mason KP, Turner DP, Houle TT, Fontaine PJ, Lerman J. Hemodynamic response to fluid management in children undergoing Dexmedetomidine sedation for MRI. American Journal of Roentgenology; 202:W574-9, 2014.

27. Mason KP, Zgleszewski SE, Prescilla R, Fontaine PJ, Zurakowski D. Hemodynamic effects of dexmedetomidine sedation for CT imaging studies. Paediatr Anaesth; 18:393-402, 2008.

28. Bhana N, Goa KL, McClellan KJ. Dexmedetomidine. Drugs; 59:263-8, 2000.

29. Dosing guidelines for Precedex®. http://www.precedex.com/wp-content/ uploads/2010/02/Dosing_Guide.pdf

30. Carollo DS, Nossaman BD, Ramadhyani U. Dexmedetomidine: a review of clinical applications. Curr Opin Anaesthesiol; 21:457-61, 2008.

31. Mason KP, Zurakowski D, Zgleszewski S, Prescilla R, Fontaine PJ, Dinardo JA. Incidence and predictors of hypertension during high-dose dexmedetomidine sedation for paediatric MRI. Paediatr Anaesth; 20:516- 23, 2010.

32. Wong J, Steil GM, Curtis M, Papas A, Zurakowski D, Mason KP. Cardiovascular effects of dexmedetomidine sedation in children. Anesth Analg; 114:193-9, 2012.

33. Kain ZN, Mayes LC, O’Connor TZ. Preoperative anxiety in children. Predictors and outcomes. Arch Pediatr Adolesc Med; 150: 1238–45, 1996.

34. Anttila M, Penttila J, Helminen A. Bioavailability of dexmedetomidine after extra vascular doses in healthy subjects. Br J Clin Pharmacol; 56: 691–3, 2003.

35. Yuen VM, Irwin MG, Hui TW. A double-blind, crossover assessment of the sedative and analgesic effects of intranasal dexmedetomidine. Anesth Analg; 105: 374–80, 2007.

36. Pandharipande PP, Pun BT, Her DL, Maze M. Effect of sedation with dexmedetomidine versus Lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA; 298:2644–53, 2007.

37. Herr DL, Sum-Ping ST, England M. ICU sedation after coronary artery bypass surgery; dexmedetomidine-based versus propofol-based sedation regimens. J Cardiothor Vasc Anesth; 17:576–84, 2003.

38. Venn RM, Grounds RM. Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions. Br J Anaesth; 87:684–90, 2001.

39. Elbaradie S, El Mahalawy FH, Solyman AH. Dexmedetomidine versus propofol for short-term sedation of postoperative mechanically ventilated patients. J Egypt Nat Cancer Inst; 16:153–8, 2004.

40. Corbett SM, Rebuck JA, Greene CM. Dexmedetomidine does not improve patient satisfaction when compared to propofol during mechanical ventilation. Crit Care Med; 33:940–5, 2005.

41. Mack PF, Perrine K, Kobylarz E. Dexmedetomidine and neurocognitive testing in awake craniotomy. J Neurosurg Anesthesiol; 16:20–5, 2004.

42. Tanskanen PE, Kytta¨ JV, Randell TT, Aantaa RE. Dexmedetomidine as an anesthetic adjuvant in patients undergoing intracranial tumour surgery: a double-blind, randomized and placebo-controlled study. Br J Anaesth; 97:658–65, 2006.

43. Wijeysundera DN, Naik JS, Beattie WS. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. Am J Med; 114:742-52, 2003.

44. But AK, Ozgul U, Erdil F. The effects of preoperative dexmedetomidine infusion on hemodynamics in patients with pulmonary hypertension undergoing mitral valve replacement surgery. Acta Anaesthesiol Scand; 50:1207–12, 2006.

45. Mason KP. Sedation trends in the 21st century: the transition to dexmedetomidine for radiological imaging studies. Pediatric Anaesthesia; 20: 265–72, 2010.

46. Berkenbosch JW, Wankum PC, Tobias JD. Prospective evaluation of dexmedetomidine for non-invasive procedural sedation in children. Pediatr Crit Care Med; 6: 435–9, 2005.

47. Mason KP, Zgleszewski SE, Dearden JL . Dexmedetomidine for paediatric sedation for computed tomography imaging studies. Anesth Analg; 103: 57–62, 2006.

48. Heard CM, Joshi P, Johnson K. Dexmedetomidine for paediatric MRI sedation: a review of a series of cases. Paediatr Anaesth; 17: 888–92, 2007.

49. Mason KP, O’Mahony E, Zurakowski D, Libenson MH. Effects of dexmedetomidine sedation on the EEG in children Pediatric Anaesthesia;19: 1175–83, 2009.

50. Ramsay MA. Tracheal resection in the morbidly obese patient: the role of dexmedetomidine. J Clin Anesth; 18:452, 2006.

51. Feld JM, Hoffman WE, Stechert MM. Fentanyl or dexmedetomidine combined with desflurane for bariatric surgery. J Clin Anesth; 18:24–8, 2006.

52. Cooper L, Samson R, Gallagher C. Dexmedetomidine provides excellent sedation for elective, awake fiber optic intubation. Anaesthesiology; 103:A1449, 2005.

53. Korogulu A, Demirbilek S, Teksan H. Sedative, hemodynamic and respiratory effects of dexmedetomidine in children undergoing magnetic resonance imaging examination: preliminary results. Br J Anaesth; 94:821–4, 2005.

54. Koroglu A, Teksan H, Sagir O, Yucel A, Toprak HI, Ersoy OM. A comparison of the sedative, hemodynamic, and respiratory effects of dexmedetomidine and propofol in children undergoing magnetic resonance imaging. Anesth Analg.; 103:63-7, 2006.

55. Shukry M, Guruli Z, Ramadhyani U. Suspected malignant hyperthermia in a child with laminin alpha2 (merosin) deficiency in the absence of a triggering agent. Paediatr Anaesth; 16:462–5, 2006.

56. Ustün Y, Gündüz M, Erdoğan O, Benlidayi ME. Dexmedetomidine versus midazolam in outpatient third molar surgery. J Oral Maxillofac Surg.; 64:1353-8, 2006.

57. Cheung CW, Ying CL, Chiu WK, Wong GT, Ng KF, Irwin MG. A comparison of dexmedetomidine and midazolam for sedation in third molar surgery. Anaesthesia; 62:1132-8, 2007.

58. Cheung CW, Ng KF, Liu J, Yuen MY, Ho MH, Irwin MG. Analgesic and sedative effects of intranasal dexmedetomidine in third molar surgery under local anaesthesia. Br J Anaesth; 107:430-7, 2011.

59. Nooh N, Sheta SA, Abdullah WA, Abdelhalim AA. Intranasal atomized dexmedetomidine for sedation during third molar extraction. Int J Oral Maxillofac Surg; 42:857-62, 2013.

60. Smiley MK, Prior SR. Dexmedetomidine Sedation With and Without Midazolam for Third Molar Surgery. Anaesthesia Progress; 61:3-10, 2014.

61. Wakita R, Kohase H, Fukayama H. A comparison of dexmedetomidine sedation with and without midazolam for dental implant surgery. Anesth Prog ; 59:62-8, 2012.

62. Kawaai H, Tomita S, Nakaike Y, Ganzberg S, Yamazaki S. Intravenous sedation for implant surgery: midazolam, Butorphanol, and dexmedetomidine versus midazolam, Butorphanol, and propofol. J Oral Implantol; 40:94-102, 2014.

63. Yoshitomi T, Kohjitani A, Maeda S, Higuchi H, Shimada M, Miyawaki T. Dexmedetomidine enhances the local anesthetic action of Lidocaine via an alpha-2A adrenoceptor. Anesth Analg; 107:96-101, 2008.

64. Obayah GM, Refaie A, Aboushanab O, Ibraheem N, Abdelazees M. Addition of dexmedetomidine to bupivacaine for greater palatine nerve block prolongs postoperative analgesia after cleft palate repair. Eur J Anaesthesiol ; 27:280–4, 2010.

65. Esmaoglu A, Yegenoglu F, Akin A, Turk CY. Dexmedetomidine added to levobupivacaine prolongs axillary brachial plexus block. Anesth Analg ; 111:1548-51, 2010.

66. Ouchi K, Koga Y, Nakao S, Sugiyama K. Dexmedetomidine dose-dependently enhances local anesthetic action of Lidocaine. J Oral Maxillofac Surg ; 72:474-80, 2014.

67. Richa F, Yazigi A. Effect of dexmedetomidine on blood pressure and bleeding in maxillo-facial surgery. Eur J Anaesthesiol; 24:985-6, 2007.

68. Taniyama K, Oda H, Okawa K, Himeno K, Shikanai K, Shibutani T. Psychosedation with dexmedetomidine hydrochloride during minor oral surgery. Anesth Prog; 56:75-80, 2009.

69. Makary L, Vornik V, Finn R, Lenkovsky F, McClelland AL, Thurmon J, Robertson B. Prolonged recovery associated with dexmedetomidine when used as a sole sedative agent in office-based oral and maxillofacial surgery procedures. J Oral Maxillofac Surg; 68:386-91, 2010.

70. Fan TW, Ti LK, Islam I. Comparison of dexmedetomidine and midazolam for conscious sedation in dental surgery monitored by bispectral index. Br J Oral Maxillofac Surg; 51:428-33, 2013.

71. Chen J, Zhou JQ, Chen ZF, Huang Y, Jiang H. Efficacy and safety of dexmedetomidine versus propofol for the sedation of tube-retention after oral maxillofacial surgery. J Oral Maxillofac Surg; 72: e1-7, 2014.

72. Shirakami G, Tanimoto K, Matsuura S, Fukuda K. Ambulatory anesthesia for an adult patient with autism and epilepsy: sedation using oral and intravenous dexmedetomidine. Masui ; 57:735-8, 2008.

73. Ogawa S, Seino H, Ito H, Yamazaki S, Ganzberg S, Kawaai H. Intravenous sedation with low-dose dexmedetomidine: it’s potential for use in dentistry. Anesth Prog; 55:82-8, 2008.

74. Kawaai H, Satoh J, Watanabe M, Kan K, Ganzberg S, Yamazaki S. A co mparison of intravenous sedation with two doses of dexmedetomidine: 0 .2 µg/kg/hr versus 0.4 µg/kg/hr. Anesth Prog;57:96-103, 2010.

75. Sazuka S, Matsuura N, Ichinohe T. Dexmedetomidine dose dependently decreases oral tissue blood flow during sevoflurane and propofol anesthesia in rabbits. J Oral Maxillofac Surg; 70:1808-14, 2012.

76. Kawaai H, Yoshida K, Tanaka E, Togami K, Tada H, Ganzberg S, Yamazaki S. Dexmedetomidine decreases the oral mucosal blood flow. Br J Oral Maxillofac Surg ;51:928-31, 2013.

77. Kim HS, Kim JW, Jang KT, Lee SH, Kim CC, Shin TJ. Initial experience with dexmedetomidine for dental sedation in children. J Clin Pediatr Dent; 38:79-81, 2013.

78. Hitt JM, Corcoran T, Michienzi K, Creighton P, Heard C.An evaluation of intranasal sulfentanil and dexmedetomidine for paediatric dental sedation. Pharmaceutics ; 6:175-84, 2014.

79. Sheta SA, Al-Sarheed MA, Abdelhalim AA. Intranasal dexmedetomidine vs. midazolam for premedication in children undergoing complete dental rehabilitation: a double-blinded randomized controlled trial. Paediatr Anaesth; 24:181-9, 2014.

80. Singh C, Pandey RK, Saksena AK, Chandra G. A comparative evaluation of analgo-sedative effects of oral dexmedetomidine and ketamine: a triple-blind, randomized study. Paediatr Anaesth Jul 25, 2014.

81. Surendar MN, Pandey RK, Saksena AK, Kumar R, Chandra G.A comparative evaluation of intranasal dexmedetomidine, midazolam and ketamine for their sedative and analgesic properties: a triple blind randomized study. J Clin Pediatr Dent; 38:255-61, 2014.